Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Ratjen

Showing results (301-310 of 326) with videos related to

Pageof 33
Sort By:
JAMA Pediatrics|February 4, 2020
Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical TrialMichael H Livingston, Sanjay Mahant, Bairbre Connolly, et al.
The New England Journal of Medicine|November 4, 2011
A CFTR potentiator in patients with cystic fibrosis and the G551D mutationBonnie W Ramsey, Jane Davies, N Gerard McElvaney, et al.
The New England Journal of Medicine|May 19, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 18, 2023
Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutationIdo Sadras, Eitan Kerem, Galit Livnat, et al.
EMBO Molecular Medicine|July 2, 2017
Orkambi® and amplifier co-therapy improves function from a rare <i>CFTR</i> mutation in gene-edited cells and patient tissueSteven V Molinski, Saumel Ahmadi, Wan Ip, et al.
Human Molecular Genetics|February 8, 2017
Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeuticsLisa J Strug, Tanja Gonska, Gengming He, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 22, 2021
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosisNico Derichs, Jennifer L Taylor-Cousar, Jane C Davies, et al.
ERJ Open Research|October 21, 2020
Multiple breath washout in bronchiectasis clinical trials: is it feasible?Katherine O'Neill, Kathryn Ferguson, Denis Cosgrove, et al.
Annals of the American Thoracic Society|November 16, 2017
CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional StudyThomas Radtke, Helge Hebestreit, Sabina Gallati, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 23, 2021
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapyDave P Nichols, Scott H Donaldson, Carla A Frederick, et al.
Pageof 33

Showing results (301-310 of 326) with videos related to

Sort By:
Pageof 33
JAMA Pediatrics|February 4, 2020
Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical TrialMichael H Livingston, Sanjay Mahant, Bairbre Connolly, et al.
The New England Journal of Medicine|November 4, 2011
A CFTR potentiator in patients with cystic fibrosis and the G551D mutationBonnie W Ramsey, Jane Davies, N Gerard McElvaney, et al.
The New England Journal of Medicine|May 19, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 18, 2023
Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutationIdo Sadras, Eitan Kerem, Galit Livnat, et al.
EMBO Molecular Medicine|July 2, 2017
Orkambi® and amplifier co-therapy improves function from a rare <i>CFTR</i> mutation in gene-edited cells and patient tissueSteven V Molinski, Saumel Ahmadi, Wan Ip, et al.
Human Molecular Genetics|February 8, 2017
Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeuticsLisa J Strug, Tanja Gonska, Gengming He, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 22, 2021
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosisNico Derichs, Jennifer L Taylor-Cousar, Jane C Davies, et al.
ERJ Open Research|October 21, 2020
Multiple breath washout in bronchiectasis clinical trials: is it feasible?Katherine O'Neill, Kathryn Ferguson, Denis Cosgrove, et al.
Annals of the American Thoracic Society|November 16, 2017
CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional StudyThomas Radtke, Helge Hebestreit, Sabina Gallati, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 23, 2021
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapyDave P Nichols, Scott H Donaldson, Carla A Frederick, et al.
Pageof 33